Congenital erythropoietic porphyria (CEP) is an autosomal recessive inborn error of metabolism that results from the markedly defi cient activity of uroporphyrinogen III synthase (UROS). We describe a 14-year-old girl with red urine since infancy, progressive blistering and scarring of the skin, and moderate hemolytic anemia. After years of skin damage, her face is mutilated; she has a bald patch on the scalp, hypertrichosis of the neck, areas of skin darkening, and limited joint movements of the hands. Total urine excretion and fecal total porphyrin were both markedly raised above normal levels. Sequencing of the UROS gene identifi ed two mutations causing CEP (Cys73Arg, Thr228Met). The patient lesions are progressing. Bone marrow transplantation and/or gene therapy are proposed as the next steps in her treatment. In brief, we describe a CEP with confi rmed two pathogenic mutations, severe phenotype and discuss the various treatment options available.
Introduction
The inherited porphyrias are disorders of heme biosynthesis resulting from the deficient activity of a specific enzyme of the heme biosynthetic pathway. [1] Depending on the site of predominant porphyrin accumulation, the porphyrias are grouped into the following two types: erythropoietic and hepatic. [2] The following three different erythropoietic porphyrias (EP) have been reported: erythropoietic protoporphyria (EPP, MIM 177000), congenital erythropoietic porphyria (CEP, MIM 263700), and hepatoerythropoietic porphyria (MIM 176100). CEP or Günther's disease is an autosomal recessive disease resulting from defi cient uroporphyrinogen III synthase (UROS) activity. [1] The clinical manifestations include chronic hemolysis, anemia, erythrodontia, and disfi guring cutaneous lesions. [3] Here, we describe a 14-yearold Macedonian girl with CEP, severe cutaneous disfi guration, and a known set of mutations (Cys73Arg, Thr228Met).
Case Report
At the age of 6 months, the patient was referred to our hospital for investigation of episodes of red urine. She was born at term after an uneventful pregnancy and delivery.
Her birth weight and length were 2 900 g and 51 cm, respectively. As a 3-week-old neonate, she received a blood transfusion for, it was believed, hemolytic anemia of the newborn. In all three of her hospital admissions, a mild hemolytic anemia was diagnosed. At the age of 6 years, she was again admitted for investigation, on this occasion with a main complaint of easy skin blistering and alkaline phosphatase were normal. Ultrasound examination of the kidneys and heart were normal and bone densitometry was unremarkable.
Now, aged 14 years, the severe photosensitive skin damage that had started in early childhood has led to disfi guring deformity of the face and hands [Figures 4 and 5] . Using all available measures to protect herself from the sun (hat, eyeglasses, cosmetic camoufl age, and long sleeves) has not succeeded in protecting her from the mutilating effects of sun. This has caused scarring of her skin at sun-exposed sites, including the backs of the hands, her face, and ears, and has resulted in bald patches on the scalp. In addition, she has restricted hand function due to scarring of the skin and has lost some of her eyelashes, which has made her eyes prone to irritation from small particles of dust. Moderate hypertrichosis on the back of the neck was also noted and her teeth have progressively stained brownish-red.
The results of the biochemical investigations are Table 1 . Total urine excretion [4] and fecal total porphyrin [5] were both markedly raised above normal levels. High-pressure liquid chromatography [6] of the urine demonstrated 85% of the uroporphyrin to be of isomer I type and fecal fractionation showed mainly coproporphyrin isomer I [ Figure 6 ]. Urinary aminolevulinic acid and porphobilinogen levels were within normal limits. The erythrocyte protoporphyrin level was greatly increased in both zinc and free forms.
Plasma fl uorescence spectroscopy revealed a prominent emission peak at 617. [7] These results confirmed a diagnosis of CEP. and c.683c>T (p.Thr228Met) in exon 10. These missense mutations have previously been described, [8] where the patient had a moderate to severe phenotype.
Discussion
CEP has an estimated frequency of 1 in every 2 to 3 million people. As of 1997, about 130 cases had been reported. [1] In Switzerland, only four cases of CEP from a total of 217 porphyrias of different types have been described. [9] CEP affects males and females equally, and has no known predilection for any ethnic group.
Mutation analysis has shown a large variety of molecular lesions. [10] Genotype/phenotype correlations have been demonstrated [10] showing that the clinical severity of the anemia and cutaneous lesions is highly mutations have <1% of normal UROS activity. [1] In case reports, a similar phenotype to that found in our patient has been reported, i.e., with severe photosensitivity and mild hemolytic anemia, but not transfusion-dependent.
[8] The profound UROS defi ciency [1] leads to a lifelong overproduction of isomer I porphyrins which are deposited in many tissues causing light-sensitization and severe damage to skin. Blistering and scarring of exposed areas may lead to mutilating deformity.
Hypertrichosis is sometimes severe.
Splenectomy, hypertransfusion, and orally administered drugs such as charcoal and cholestyramine, which binds porphyrins have also been used to treat CEP. Unfortunately, these classical treatments are unsatisfactory and do not effectively control the disease. In murine models, oncoretroviral and lentiviral vectors were used to successfully transduce HSCs, allowing full metabolic and phenotypic correction of both EPP and CEP mice. [11, 12] These results form the basis for gene therapy clinical trials in severe forms of EP.
In conclusion, we have described a 14-year-old girl with CEP, with defi ned UROS mutations and severe phenotype. BMT and gene treatment have been discussed with the parents as further treatment options.
